Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
This is especially the case for people globally who don’t have access to such newer regimens.
Findings suggest exposure to antiretrovirals, including dolutegravir, during pregnancy does not raise the risk of neural tube defects.
Researchers have called for revised treatment guidelines to address the higher risk of fracture in the HIV population.
Researchers at George Washington University take a look.
The integrase inhibitor–based HIV regimen was compared with dolutegravir-based regimens.
The experimental long-acting injectable regimen of cabotegravir and rilpivirine stands poised for approval.
Participants in a study were started on daily oral drugs and then half were switched over to long-acting meds.
This held true even among those with resistance to nucleoside/nucleotide reverse transcriptase inhibitors.
Research in human cells and mice found the antiretroviral suppressed harmful chronic inflammation linked to age-related disorders.
More high-quality evidence is needed to determine how this class of HIV medications may affect weight gain.
Gilead Sciences has released 96-week results from an ongoing double-blinded study comparing the two regimens.
So argued researchers behind a study that switched people from triple-antiretroviral regimens to Tivicay monotherapy.
This is according to a French study looking at discontinuations of Tivicay compared with Vitekta and Isentress.
A large ongoing study in Botswana has found that about 1 in 150 babies exposed to Tivicay at conception developed such birth defects.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.